|
|
 | | | |
- close
- close
- close
- close
StreetInsider.com
May 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medivation%2C+Inc.+%28MDVN%29+Tops+Q1+EPS+by+5c%3B+Names+Directors/8323822.html for the full story.
Benzinga
May 9
Comment
In a report published Thursday, Goldman Sachs analyst Navdeep Singh reiterated a Buy rating and $68.00 price target on Medivation (NASDAQ: MDVN).
In the report, Singh noted, “Medivation is scheduled to report Q1:13 earnings after market close...
Benzinga
May 9
Comment
Analysts at Benchmark initiated coverage on shares of Merit Medical Systems (NASDAQ: MMSI) with a “hold” rating. The target price range for Merit Medical Systems is set to $10. Merit Medical Systems' shares closed at $10.00 yesterday....
Benzinga
May 7
Comment
Analysts at Piper Jaffray initiated coverage on shares of Rally Software Development Group (NASDAQ: RALY) with an “overweight” rating. The target price range for Rally Software Development is set to $23. Rally Software Development's shares...
Benzinga
Apr 29
Comment
Medivation (NASDAQ: MDVN) today announced that Wendy Yarno has been elected to the Company's Board of Directors. Ms. Yarno has over 26 years of experience in the pharmaceutical industry at Merck & Co. Inc., holding a number of executive positions...
StreetInsider.com
Apr 26
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Astellas%2C+Medivation+%28MDVN%29+Receive+Positive+CHMP+Opinion+on+XTANDI/8281705.html for the full story.
Benzinga
Apr 23
Comment
Medivation (NASDAQ: MDVN) today announced that Dawn Graham has been elected to the Company's Board of Directors. Ms. Graham joins Medivation following a 23-year career in pharmaceutical commercial leadership positions at Merck & Co. Inc., from...
Benzinga
Apr 4
Comment
Medivation (NASDAQ: MDVN) shares are up more than 5 percent Thursday following some bullish comments from Jefferies' Biren Amin.
The comments follow recent investor meetings with Medivation management which left Amin feeling like "the state of...
StreetInsider.com
Apr 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medivation+%28MDVN%29%2C+Astellas+Plan+Inteim+Update+for+XTANDI+Phase+III/8220415.html for the full story.
Benzinga
Mar 4
Comment
Analysts at Piper Jaffray initiated coverage on shares of Oncolytics Biotech (NASDAQ: ONCY) with an “overweight” rating. The target price range for Oncolytics Biotech is set to $6. Oncolytics Biotech's shares closed at $3.36 on Friday....
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_2/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_2/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800. |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
